Concepedia

Author

Patrick W. Vincent

Pfizer (United States)

Also Known As

P Vincent, P W Vincent, P. VINCENT, P. Vincent, Patrick VINCENT, Patrick Vincent, Patrick W. Vincent, Viana De Gra, Vincent, Patrick

130

Publications

7.7K

Citations

29

H-Index

74

Concepts

All Affiliations

Pfizer (United States)University of AucklandUniversité de MontréalCancer Society of New ZealandLaboratoire de Biogenèse Membranaire
PW

About

Patrick W. Vincent is an author at Pfizer (United States) specializing in medicine, pharmacology, and natural sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

19

5.3K

2

Natural Sciences

9

9

714

3

Health Sciences

2

2

113

4

Public Health

1

1

16

5

Allergy

1

1

32

Patrick W. Vincent

×

39

Publications

7.2K

Citations

26

H-Index

YearCitations

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang,

Cancer Research

2004

4K

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib

Jeffrey A. Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale,

Cancer Research

2007

713

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor:  4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions

Jeff B. Smaill, Gordon W. Rewcastle, Joseph A. Loo,

Journal of Medicinal Chemistry

2000

263

Induced Pluripotent Stem Cell Lines Derived from Equine Fibroblasts

Kristina Vintersten Nagy, Hoon‐Ki Sung, Puzheng Zhang,

Stem Cell Reviews and Reports

2011

246

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

Andrea J. Gonzales, Kenneth E. Hook, Irene W. Althaus,

Molecular Cancer Therapeutics

2008

220

A Sec14p-nodulin domain phosphatidylinositol transfer protein polarizes membrane growth of <i>Arabidopsis thaliana</i> root hairs

Patrick W. Vincent, Michael Chua, Fabien Nogué,

The Journal of Cell Biology

2005

211

Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)pyrido[<i>d</i>]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor

Jeff B. Smaill, Brian D. Palmer, Gordon W. Rewcastle,

Journal of Medicinal Chemistry

1999

178

2-Substituted Aminopyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-ones. Structure−Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity

S. KLUTCHKO, James M. Hamby, Diane H. Boschelli,

Journal of Medicinal Chemistry

1998

130

Tyrosine Kinase Inhibitors. 14. Structure−Activity Relationships for Methyl- amino-Substituted Derivatives of 4-[(3-Bromophenyl)amino]-6-(methylamino)- pyrido[3,4-<i>d</i>]pyrimidine (PD 158780), a Potent and Specific Inhibitor of the Tyrosine Kinase Activity of Receptors for the EGF Family of Growth Factors

Gordon W. Rewcastle, Donna K. Murray, William L. Elliott,

Journal of Medicinal Chemistry

1998

112

Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-<i>d</i>]pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor

Jeff B. Smaill, H. D. Hollis Showalter, Hairong Zhou,

Journal of Medicinal Chemistry

2000

89

Page 1